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Proteins of the annexin/lipocortin family have been claimed 
to mediate the anti-inflammatory action of glucocorticoster-
oids by the inhibition of phospholipases A2, This hypothesis 
has been challenged by the finding that annex ins do not 
directl y interact with the enzyme in a classical enzyme/inh i-
bitor behavior, but more likely block the access of the phos-
pholipase A2 to its substrate by binding to phospholipids. 
Because former studies with skin phospholipase A2 suggested 
a specific regulation by annexin-l, we investigated the sub-
strate dependence of this effect. For this purpose phospholip-
ase A2 activities in human epidermis and dermis homogenates 
were measured in the presence of various amounts of annex-
ins-l, -2, or -5. The respective annexin was preincubated in 
separate series either with the substrate or with the enzyme. 
We found a partial inhibition of both epidermal and dermal 
phospholipase A2 activities with all annexins tested (an-
P hospholipases A z (EC 3.1.1.4) are a group of enzymes that hydrolyze the ester bond of fatty acids from the sll-2-position of phospholipids. The release of arachi-donic acid from membranes by phospholipases Az and its subsequent conversion into leukotrienes, prostaglan-
dins, and other eicosanoids is an important catalytic event in the 
process leading to inflammation. Additionally, phospholipases Az 
are involved in the biosynthesis of platelet-activating factor (PAF). 
Based on amino acid sequence data , phospholipases Az have been 
divided into two groups [1] . Group I encompasses pancreatic, Elapi-
dae (cobra), and Hydrophidae (sea snake) venom enzymes. Group II 
enzymes are found in Crotalidae and Viperidae and contain at the 
carboxy terminal of the molecule an extension of six or seven resi-
dues that are absent in group I phospholipases A2. Extracellular 
phospholipases Az, which are regarded to be involved in inflamma-
tion, have been found to belong to group II. Recently, a third type of 
phospholi~ase A2 with a molecular weight of 85 kD has ?een char-
acterized 12,3]. ThiS enzyme IS found 111 the cytosol and IS active at 
the low calcium concentrations present in the cytosol. It has been 
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nexin-5 ~ annexin-2> annexin-l). The inhibitory effect 
was abso lutely dependent on the annexin/phospholipid ratio 
and occurred only at very high annexin concentrations rela-
tive to the amount of substrate. 
Our data demonstrate that the inhibition of human skin 
phospholipase A2 by annexins depends on the substrate con-
centrations , as has been shown for phospholipases A2 of other 
origins as well. All observations can be explained by the 
current "substrate depletion model" characterizing the indi-
rect effects of annexins on phospholipase A2 activities. It is 
therefore rather unlikely that annexins are directly involved 
in the regulation of phospholipase A2 activity of human skin 
under physiologic conditions. Key words: Phospholipase A2/ 
annexins/ corticosteroids. ] 1mlest Derrnatol 101 :359-363, 
1993 
cl ai~ed to hyd:olyze specifica ll y phospholipids that have arachi-
dome aCid estenfied at their 511-2 position and it is possibly involved 
in the release of eicosanoids and intracellular signaling. 
Although a vanety of agents block either prostaglandin or leuko-
triene production, compounds that inhibit both pathways, such as 
the glucocorticoids, have proved to be the most potent anti-inflam-
matory age~ts. During the last 10 years a group of structurally 
related, calclllm-dependent phospholipid-binding proteins has been 
discovered (see [4] for review) . These proteins had been shown by 
numerous investigators to be inducib le by glucocorticoids and to 
inhibit phospholipase Az activity irl lIitro (see [5] for review). These 
independent observations led to the hypothesis that the inhibition 
of phospholipase A2 by this group of proteins is the mechanism of 
the anti-inflammat.ory action or glucocorticoids. Based on this sug-
gested mode of actIOn they were initially termed lipocortins. Later, 
they were renamed using the more general term annexin [6]. 
. In th~ last f~w years, th~ ide~ that the proteins of the annexin/ 
t.pocortl11 family are phYSIOlogIC regulators of phospholipases A z 
has been challenged by several observations. First it became obvious 
that ~lot only ph.ospholipase Az but also phospholipase C and phos-
phohJ?ase Dare II1hlblted by "lipocortin" under similar assay condi-
tions 17]. Later, this inhibition was shown to be dependent on the 
assay conditions, i.e., the concentration of the substrate [8,9]. Fi-
nally, .the hypothesized regulatory link between the synthesis of 
annexl11-1 and glycocorticoids on a pre-transcriptional level could 
not be demonstrated by all investigators [10,11]. In short, these 
findings placed the "Iipocortins" beyond the scope of their original 
definition as being i) glycoproteins whose ii) synthesis or secretion is 
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stimulated by glucocorticoids and that iii) specifically inhibit phos-
pholipase Az . Therefore, these rel ated proteins are now referred to 
as annexins [6] . 
Phospholipase A z activity has been found in human skin, and 
raised levels have been described in lesional and non-lesional psori-
atic skin. Thus, the release of arachidonic acid by epidermal phos-
pholipase Az and its subsequent conversion to leukotriene B4 and 
other lipid mediators could represent a pivotal mechanism in the 
mediator cascade leading to inflammation and immigration of gran-
ulocytes [12] . Phospholipase Az activity in human epidermis has 
been claimed to be specifically inhibited by lipocortin l/annexin-1 
even at high substrate concentrations [13]' suggesting a distinct 
behavior of human ski n phospholipase Az in comparison to other 
phospholipases Az [8,9]. The hypothetic regulation by annexins to 
characterize human skin phospholipase Az or to monitor topical 
steroid action by the measurement of phospholipase A z has also been 
used [14,15]. In the following study, we wanted to investigate the 
influence of the substrate concentration on the inhibition of human 
skin phospholipase Az by annexins. Furthermore, we asked whether 
the inhibition of skin phospholipase Az is specific to annexin-1, or 
whether other annexins inhibit human skin phospholipase A2 as 
well. 
MATERIALS AND METHODS 
Tissue Preparation Full-thickness skin was obtained from human ca-
davers during the first 24 h post-mortem and carefully freed from adjacent 
fat lobules. After incubation in2 M potassium bromide for 30 min at 37"C, 
specimcns wcre rinsed with an ice-cold 0.9% (w/v) NaCI solution for 10 
min. The epidermis was separated from the dermis with fine forceps, and the 
dermal and epidermal fractions were collected on ice. After the tissue had 
becn dried with paper towels, the tota l weight was determined, and the 
specimens were snap frozen with liquid nitrogen and stored at - 80·C in 
plastic tub~s. Tissue homogenization was carried out in a 0.9% (w/v) NaCI 
solution on icc in the prcsence of 1 mM phenylmcthylsulphonyl fluoridc 
with a Turrax homogenizer, and subsequently with an all-glass Potter 
grinder. After centrifugation of the homogcnates at 10,000 X g for 15 min, 
the supcrnatants were stored at -80·C for further processing. Determina-
tion of protein was done according to Bradford [16J. 
Isolation of the Annexins Annexins were purified as described previ-
ously [17]. Briefly, freczc-dricd human placcnta was extracted with buffcr 
containing citrate. After removaI of the cell dcbris thc annex ins were puri-
fied by chromatography on phenyl, (calcium) hcparin, and Q-Scpharosc, 
yielding a > 95% pure preparation. 
Phospholipase A2 Assay I-palmitoyl-2-[1- '4c]-arachidonyl-stl-gly-
cero-3-phosphoethanolamine (New England Nuclcar, Boston, MA) was 
diluted with l,2-dipalmitoyl-stl-glycero-3-phosphoethanolamine (Sigma, 
St. Louis, MO) to the desired substratc concentrations and specific radioacti-
vities. The lipid mixture was dried under nitrogen and dissolved in water. 
This emulsion was sonified twO times for 1 min with 60 W under a constant 
flow of nitrogen. Then the buffer containing 100 mM Tris-HCI, pH 7.0, 
and 10 mM Ca++ was added. Three different substrate emulsions with re-
spective phospholipid concentrations of 211M, 10 11M, and 200 11M were 
prepared. In these emulsions the unlabeled dipalmitoyl-phosphatidyletha-
nolamine was the predominant phospholipid (0.27%, 2.7%, and 13.6%, 
respectively). Due to the high melting point of the dipalmitoyl-phosphati-
dylethanolamine, the physical state of the phospholipids is a bilayer. All 
experimcnts at a substrate concentration of 2 nM were also performed with 
1-palmitoyl-2-[1- 14c] -arachidonyl-sn- glycero-3-phosphoethanolaminc 
alone to exclude an interference of the relatively higher amount of this 
phospholipid in this preparation. No significant difference in the inhibition 
patterns was found. For each substrate the linearity of hydrolysis was deter-
mined and experiments were carried out within this range. 
Annexins-1, -2, and -5 were diluted with 20 mM Tris-HC1, pH 7.5, 
150 mM NaCI, BSA 0.1% (w/v) to varying concentrations, as specified in 
the legends of the figures. The annexins wcre preincubated either with the 
tissue homogenates (assay A) or with thc substrate emulsion (assay B) for 15 
min at 37"C. The assay was started by the addition of the substrate (assay A) 
or the homogenates of epidermis or dermis, respectively (assay B). After a 
maximal incubation time of 15 min at 37"C, the reaction was stopped, and 
released [14C]-arachidonate was determined by a modified Dole extraction 
procedure as described [t 8]. The activity was expressed in mU /ml, reflecting 
the amount of arachidonic acid in tlmol released by 1 ml homogcnate per 
minute. Inhibition was expressed as the percentage of phospholipase Az 
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activity compared to a control containing no annexin. All cxperiments, 
including blanks containing neither enzyme nor annexins, were carried out 
in duplicate. 
For the statistical anal ysis the test for the equaliry of slopes according to 
Draper and Smith was applicd. A p < 0.05 was regarded as statistically 
significant. 
RESULTS 
The tissue homogenates used had a specific phospholipase Az activ-
ity of 24 mU and 13 mU per mg of protein for the epidermal and 
dermal homogenates, respectively (means of four different experi-
ments). Initial inhibition studies at a substrate concentration of 
200 tiM and an annexin concentration of 27 nM showed no clear 
effect of the three alU1exillS added, independent of the preincuba-
tion procedure of the annexins. Only annexin-5 dccreased the en-
zyme activity by 10% in the dermal fraction and 30% in the epider-
mal fraction, when it was preincubated with the substrate (data not 
shown) . In subsequent experiments we continuously decreased the 
assay concentration of the substrate to study the effect of lower 
substrate/annexin ratios. The lowest substrate concentration tested 
was 2 tiM, and here an inhibition of95% and 75% could be demon-
strated with 270 nM allnexin-5 and epidermis and dermis, respec-
tively (Fig IB) . Annexin-l and annexin-2 displayed maximal inhi-
bitions of 45% and 65% with dermis and 57% and 72% with 
epidermis under these conditions. These effects gradually decreased 
with rising substrate concentrations for all annexins (Fig 1Al B). 
To investigate the influence of the incubation procedure we ran 
separate series, preincubating the annexin either with the substrate 
or with the tissue homogenate. When the annexins were preincu-
bated with the substrate (Fig IB) the inhibition was stronger than 
the inhibition found after preincubation with the enzyme (Fig 1A). 
In the dermis this effect reached a significant level only for annexin-
2 (p = 0.001) and annexin-5 (p = 0.012). For the epidermal frac-
tion this dependency on the incubation procedure only became ap-
parent with annexin-5 (p = 0.004). 
Under constant substrate concentrations the inhibitory effect was 
found to be dependent on the concentration of the respective an-
nexin. Figure 2 shows that annexin-5 is about 100 times more 
effective than annexin-l and annexin-2 in inhibiting both tissue 
homogenates . Fifty percent of the activity of the epidermal phos-
pholipase Az was inhibited in the presence of 3.5 pmol/ml of an-
nexin-5, whereas 200 pmol/ml of annexin-l or annexin-2 were 
needed to obtain the same effect. These inhibition profiles of the 
three annexins were comparable to those obtained with dermal 
phospholipase Az where, due to the overall weaker inhibition of this 
fraction, 50% inhibition values for annexin-l and annexin-2 were 
not determined. 
As can be seen in Figs 1 and 2, the inhibition profiles of the 
epidermal and dermal phospholipase A2 differed. Under the same 
assay conditions epidermal phospholipase Az was inhibited more 
strongly than dermal phospholipase A2 at low substrate concentra-
tions (Fig 1) . But these difference were only significant when the 
annexins were preincubated with the enzyme (Fig 1A) with p = 
0.012 for annexin-1 , p = 0.025 for annexin-2, and p = 0.0005 for 
annexin-5 . 
The correlation of the enzyme activity with the molar ratio of 
substrate and annexin showed the phospholipase Az inhibition of all 
annexins to be a function of the quantitative relation of substrate and 
annexin molecules (Fig 3) . Here again, the higher inhibitory poten-
tial of annexin-5 is obvious, whereas annexin-l and annexin-2 were 
similar in their inhibition profiles. 
To investigate whether the inhibitory effect also depends on the 
amount of enzyme, we incubated annexin-5 at a concentration of 
27 nM with increasing amounts of the homogenates of epidermis 
and dermis, as depicted in Fig 4. In this experiment the amount of 
inhibition decreased with rising concentration of the enzyme 
added, suggesting a competition of phospholipase A2 and annexin 
for the binding to the substrate (Fig 4) . 
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Figure 1. Phospholipase A2 activity in homogenates of ?crmis (clo~ed 51'111-
bois) and epider.mls (opel/ symbols) 111 the presence of annex1I1-1, annex111-2, or 
annexin-5 at dIfferent substrate concentra tIons. Values represent means of 
three independent experiments performed in duplicate. Error bars, SEM; data 
points lacking error bars have a SEM below 2%. To avoid any overlaps, in 
some cases only one-ha lf of the error bar is displayed. Annexins were pre- in-
cubated at a concentration of 270 nM with the enzyme (A) or with the 
substrate (B). 
DISCUSSION 
In this study we demonstrate that an inhibitory effect of annexins on 
phospholipase A2 of human skin occurs on ly at high annexin/phos-
pholipid ratios. Hence, phospho lipase A2 activity in human skin 
homogenates shares this property with other phospholipases A2like 
rat liver mitochondrial phospholipase A2 [8] and porcine pancreatic 
phospholipase A2 [9]. 
From the observed influence of the substrate concentration and 
the finding that the annexin does not bind to the enzyme, but much 
more tightly to the substrate [19], the so-call ed 'substrate depletion 
model' of the annexin action had been derived [9] . According to this 
model, the annexin binds to the phospholipid substrate, forming a 
substrate-inhibitor complex. T his complex is especially tight for the 










































Fi~ure ~. Phospholipase A2 activi.ty in homogenates of dermis (A) and 
epldernl1s (B) 111 the presence of nS1l1g concentrations of annexins-l , -2, or 
-5. Annexins were pre-incubated with the substrate at a concentration of 
phosphatidylethanolamine of 10 tiM. Values represent means of two inde-
pendent expenments performed in duplicate. Error bars, SEM; data points 
lack1l1g error bars have a SEM below 2%. To avoid any overlaps, in some 
cases only one-half of the error bar is displayed. 
calcium ions. By this substrate-inhibitor interaction, the access of 
phospholipase A2 to its substrate is impaired, and a competition of 
phospholtpase A2 and annexin for the substrate results. This is in 
accordance w ith the difference of the inhibition patterns in de fen-
dence on the 111cubation mode in our study (Fig 1). Only i the 
substrate concentration is sufficiently low relative to the amount of 
annexin does an inhibitory effect become apparent. Considering the 
fact that only a restricted fraction of the phospholipids of the, mi-
celles can be hydrolyzed by phosphol ipases, the effective ratio of 
annexins to substrate might even be lower than depicted in Fig 3. 
Under physiologic conditions such ratios are highly unlikely to 
occur. III lIillo substrate is not a limiting factor, and very high con-
centrations of annexins would be necessary to give any biologic 
effect. 
A potentiation of the i,·, lIitro effect of annexins can occur in the 
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Figure 3. Inhibition of phospholipase Az activity in homogenates of dermis (A) and epidermis (B) as a function of the molar ratio of substrate and 
annexin-1 , -2, and -5. Annexins were pre- incubated with the substrate. 
X-axis, molar ratio of substrate to annexin. The absolute ratios of substrate to 
annexin fo r the individual data points arc: x = 7.4 (2 J.lM/270 nM); x = 37 
(10 J.lM/270 nM) ; x = 74 (2 J.lM/27 nM); x = 370 (10 J.lM/27 nM); x = 
740 (200 J.lM/270 nM) ; x = 3700 (10 J.lM/2.7 nM); x = 7400 (200 JiM/ 
27 nM); x = 3.7 ·10' (1 0 J.lM/ 0.27 nM); x = 3.7 '10s (10 J.lM/ 0.027 nM) . 
presence of deoxycholate in the assay mixture. D eoxycholate is 
necessary w hen phosphatidylcholine (PC) is used as substrate in 
phospholipase A2 assays and can form complexes w ith th e calcium 
in t he assay mixture. In the presence of annex ins, which will also 
need calcium ions to bind to th e phospholipids, th e calciu1!l concen-
tration can become critically low. This depletion of calcium can 
decrease phospho lipase A2 activity, w hich is absolutely ca lcium de-
pendent. Therefore, deoxycholate/PC mixtures as phospholipase 
A2 assay systems are regarded as unsuited to study th e effects of 
annexins [9 ,20] . O ther investi gators omitted additional calcium 
from th e assay mixture, so th at a competition between annexins and 
phospholipase A2 for calcium in the assay could have occurred. 
Our results are contradictory to the findin g of Cartwri ght el al 
[13] . W e could no t find any significa nt inhibition of epidermal 
phospholipase A2 by annexin-l above a ratio of substrate/ annexin of 
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Figure 4. Inhibition of phospholipase Az activity in dermis and epidermis 
homogenates in the presence of 27 11M annex in-5 in dependence of the 
amount of homogenate added. The annexin was pte-incubated with the 
substrate at a concentration of phosphatidylethanolamine of 50 J.lM. Values 
represent means of two independent experiments performed in duplicate. 
Error bars, SEM; data points lacking error bars have a SEM below 2%. To 
avoid any overlaps, in some cases only one-half of the error bar is displayed. 
50. This difference might be due to the above-mentioned problem-
atic nature of the deoxycho late/PC mixture used in their study. The 
50% inhibitory concentration of annexin- l in our study is in ac-
cordance with the findings o f authors who investigated phospholip-
ase A2 from other sources:!: [8 ,21]. Interestin gly , annexin-5 dis-
played a 100 times higher inhibitory potential than annexin-l. This 
is in accordance with the very potent anti-coagulatory effects of 
annexin-5 ill vitro. Because annexin-5 has a strong binding affinity 
to phospholipid m embranes , comrarable to that of the factors Va 
and X a to platele t m embranes [22 , it is able to compete for activa-
tion surfaces. Whether this anticoagulant mechanism is of physio-
logic relevance is, however, questionabl e [23]. 
Since the investigation of Ziboh et III [24,25]' human skin is 
known to contain considerable phospholipase A2 activity . Later on, 
raised levels of phospholipase A2 w ere found in association with 
inflammatory skin disorders, i.e. , psorias is vul garis [26] . Up to now, 
no attempt has been made to charac terize the phospholipase A2 
activity found in human epidermis with regard to the possible 
groups of phospholipases A2 stated above. Studies on other inflam-
m atory disorders like rheumato id arthritis made it likely that at least 
the maj ority o f the phospho lipase A2 activity found in human skin 
can be assigned to a group II phospho lipase A2 [27] . This assumption 
is substantiated by the findin g that antibodies against pancreatic 
phospholipase A2 do not crossreact with phospholipase A2 from 
human skin, and that human epidermal phospholipase A2 differs 
from human pancreatic phospholipase A2 in solubility and pH op ti-
mum.§~ By analyzing th e inhibition patterns of annexin-l with 
skin phospho lipase Az, it has been concluded that ho mogenates of 
human epidermis may contain different phospholipases A2. Bergers 
et al described a phospholipase A2 ac tivity in the upper epidermis 
that could not be modul ated by pretreatment with corticosteroids or 
by the addition of alkaline phosphatase, indirectly implicating a lack 
:j: Davidson FF, Lister MD, Glaser KB , Dennis EA: Analysis of the inhibi-
tion of phospholipase Az by lipocortins and calpactins (abstr).] Cell Bioi 
107:425, 1989. 
§ Bastian BC, Seekamp A W , Burg G: Measurement of human epidermal 
and dermal phospholipase Az using anionic substrates (abstr).] III IIes t Dermo-
iol 96:627,1991. 
~ Seekamp A W . Franz S, Burg G, Bastian BC: Partial characterization 
and immunohistochemical locali sation of phospholipase A2 of human skin 
(abstr).] IIIIIest Derlllatol 96: 1010, 1991 . 
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of regulation by annexin-1 [14] .. In this study an artificial assay 
system with 30% dimethylsulfoxide was used. In the ~resence of 
30% dimethylsulfoxide, phospholtplds do not form btlayers but 
give a solution of monomers .. According to the substrate deplet~on 
model described above, annexms would probably not be able to bmd 
to phospholipids in monomeric sol.u~ions and thereby become un-
ble to inhibit phospholtpase A2 activity. Moreover, no controls for 
: positive modulation by alkaline phosphatase under these assay 
conditions were used . Therefore, it remains un~lear whether the 
lack of regulation by annexms was a specific attnbute of the phos-
holipase A2 studied or due to the assay conditions used: In sh~rt, 
fhe growing body.of eVidence that the cl~aractenstlc ofbemg I11hlb-
ited by annexins IS not a specific cntenon for ~hospholtpases A2 
makes this approach unsUited for the classification of Rhosphol.l-
pases A2. Evidence for the eXistence ?f different phosphohpase A2 m 
human epidermis has also been denved frol~l the observation th~t 
the inhibition of human epidermal phosphohpase A2 by annexms IS 
not complete. From this finding, Cartwright el at postulated the 
presence of an annexin-sensitive and a non-sensitive form of phos-
pholipase A2 in human epidermiS [13]. But experiments .wIth .pu~e 
hospholipase A2 of different sources also showed a maXimal I11hl-
ttion of 70% [8]. Disregarding the problems of the phospholipase 
A assay used in this study, as stated above, this incomplete inhibi-
ti~n alone does not prove the existence of a second phosphol!pase 
A . Thus, evidence for the presence of several blochenucally dtffer-
e~t A phospholipases in human epidermis is still lacking. 
In ~ur study, the inhibition profiles of the dermal and epidermal 
homoge nates showed significant. differences. !he epidermal frac-
tion was inhibited at lower annexm concentrations than the dermal 
fraction. Whether this is due to a true difference in the phospholip-
ases of both fractions or to additional factors present in the homoge-
nates remains to be established in further experiments with purified 
enzymes. .. . 
Annexins-1 and -2 are abundantly present 111 human epldenms 
and dermis [28], and an increased expression has been found in 
well-differentiated squamous cell carcinomas and in benign hyper-
proliferative skin disorders. *.* Their definite function still remains 
unclear. Analysis of the tertiary structure of annexm-S revealed.a 
symmetric n~olecule with ion-ch~nnel characteristics. The amplu-
pathic annexI.ns ca~ probably partially penetrate the m embrane and 
channel ions m a stdl unknown way [29,30]. Annexl11s may thus 111 
some way playa role in inflammation, growth regulation, or onco-
genesis, but it appears unlikely that they are directly involved in the 
regulation of phospholtpase A2· 
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